In This Article, You'll Discover Understanding how NerveFreedom's unique formulation addresses multiple aspects of ner ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

Patients with occipital headache experienced relief with 60 days of peripheral nerve stimulation, according to data presented ...

Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach.

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

A sutureless device for peripheral nerve repair by medical technology company Tissium, which has its US office in Cambridge, could be available on the market in the coming months.

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of ...

The Global Neuropathic Pain Market is valued approximately at USD 8.14 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.73% over the forecast period 2024-2032.

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to TISSIUM’s COAPTIUM CONNECT, representing the first atraumatic option for repairing peripheral nerve damage.

The surgical sealant developer Tissium obtained a groundbreaking FDA clearance for its method of reconnecting severed nerves, ...